Update on Biologics in Treatment of Chronic Rhinosinusitis With Nasal Polyposis

초록

Chronic rhinosinusitis is a common chronic inflammatory condition of sinonasal cavities andoccurs with or without nasal polyps. Uncontrolled chronic rhinosinusitis with nasal polyp(CRSwNP) has a negative impact on an individual’s quality of life. Many studies have beenconducted for novel treatments targeting type 2 cytokines involved in CRSwNP such as interleukin(IL)-4, IL-5, IL-13 and immunoglobulin E. Biologics have recently been proven to improvethe nasal symptoms of CRSwNP and reduce the need for systemic glucocorticosteroids. Recently dupilumab, omalizumab and mepolizumab were approved by Food and Drug Administrationfor CRSwNP, and other biologics are under investigation. Large-scale and longtermclinical trials are needed for therapeutic effectiveness, and several questions remain regardingpatient selection, treatment algorithm, and cost-effectiveness. Nevertheless, emergingbiologics may offer a new therapeutic option for uncontrolled CRSwNP.

키워드